Publications by authors named "N S Schenkman"

Objectives: To assess the safety and efficacy of using microwave ablation (MWA) to treat solitary kidney (SK) patients with T1a renal cell carcinoma (RCC).

Methods: Retrospective analysis of a prospectively maintained database identified patients with T1a RCC with either congenital or acquired SK. Estimated glomerular filtration rate (eGFR) was calculated from serum creatinine before MWA and after at 6 and 12 months post-procedure.

View Article and Find Full Text PDF

Objective: To examine the cost-effectiveness of the clear cell likelihood score compared to renal mass biopsy (RMB) alone.

Methods: The clear cell likelihood score, a new grading system based on multiparametric magnetic resonance imaging, has been proposed as a possible alternative to percutaneous RMB for identifying clear cell renal carcinoma in small renal masses and expediting treatment of high-risk patients. A decision analysis model was developed to compare a RMB strategy where all patients undergo biopsy and a clear cell likelihood score strategy where only patients that received an indeterminant score of 3 undergo biopsy.

View Article and Find Full Text PDF

Objective: To compare the oncological and renal function outcomes of microwave ablation (MWA) compared to partial nephrectomy (PN) in two small renal mass (SRM) tumor size cohorts, <3 cm and 3-4 cm.

Materials And Methods: This study included retrospective data from 2009 to 2015 and prospective data since 2015 from a single-institution database. Patient demographics, renal mass characteristics, and treatment outcomes were collected.

View Article and Find Full Text PDF

Purpose: To compare the oncological and renal function outcomes for patients receiving microwave ablation (MWA) in tumors < 3 and 3-4 cm.

Methods: Retrospective analysis of a prospectively maintained database identified patients with < 3 or 3-4 cm renal cancers undergoing MWA. Radiographic follow-up occurred at approximately 6 months post-procedure and annually thereafter.

View Article and Find Full Text PDF
Article Synopsis
  • In April 2022, GE Healthcare's interruption in iohexol manufacturing caused a global iodinated contrast shortage, severely affecting urological practices and highlighting the need for alternative solutions.
  • A literature review identified older iodinated contrast agents, gadolinium-based agents, and various lesser-known imaging techniques as viable substitutes, alongside strategies for conserving contrast.
  • The findings emphasize the necessity for urologists to adapt by utilizing these alternatives and preparing for potential future shortages due to the significant impact of the iohexol deficit on patient care.
View Article and Find Full Text PDF